ABMT (Advanced BioMedical Technologies) ROC %: -263.53% (As of Jul. 2021)


What is Advanced BioMedical Technologies ROC %?

Advanced BioMedical Technologies ABMT ROC % is -263.53% as of Jul. 2021.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Advanced BioMedical Technologies's annualized return on capital (ROC %) for the quarter that ended in Jul. 2021 was -263.53%.

As of today (2026-06-28), Advanced BioMedical Technologies's WACC % is 0.00%. Advanced BioMedical Technologies's ROC % is 0.00% (calculated using TTM income statement data). Advanced BioMedical Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Advanced BioMedical Technologies  (OTCPK:ABMT) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Advanced BioMedical Technologies's WACC % is 0.00%. Advanced BioMedical Technologies's ROC % is 0.00% (calculated using TTM income statement data). Advanced BioMedical Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Advanced BioMedical Technologies ROC % Related Terms

Advanced BioMedical Technologies ROC % Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies ROC % Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -509.39 -602.99 -782.72 -357.99 -36.79

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -238.17 -51.89 -42.53 -265.88 -263.53

Advanced BioMedical Technologies ROC % Calculation

Advanced BioMedical Technologies's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2020 is calculated as:

ROC % (A: Oct. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Oct. 2019 ) + Invested Capital (A: Oct. 2020 ))/ count )
=-0.321 * ( 1 - 0% )/( (0.236 + 1.509)/ 2 )
=-0.321/0.8725
=-36.79 %

where

Invested Capital(A: Oct. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.219 - 6.561 - ( 0.006 - max(0, 6.697 - 0.119+0.006))
=0.236

Invested Capital(A: Oct. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.469 - 6.493 - ( 0.202 - max(0, 7.864 - 0.331+0.202))
=1.509

Advanced BioMedical Technologies's annualized Return on Capital (ROC %) for the quarter that ended in Jul. 2021 is calculated as:

ROC % (Q: Jul. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2021 ) + Invested Capital (Q: Jul. 2021 ))/ count )
=-0.448 * ( 1 - 0% )/( (0.175 + 0.165)/ 2 )
=-0.448/0.17
=-263.53 %

where

Invested Capital(Q: Apr. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.379 - 8.334 - ( 0.006 - max(0, 8.348 - 0.218+0.006))
=0.175

Invested Capital(Q: Jul. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.397 - 8.568 - ( 0.007 - max(0, 8.579 - 0.243+0.007))
=0.165

Note: The Operating Income data used here is four times the quarterly (Jul. 2021) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -263.53% mean?
Advanced BioMedical Technologies (ABMT) has a ROC % of -263.53% as of Jul. 2021. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' ROC % too high?
Advanced BioMedical Technologies' current ROC % is -263.53%.
How does Advanced BioMedical Technologies' ROC % compare to VYCO and ADMT?
Advanced BioMedical Technologies' ROC % of -263.53% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.26, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Advanced BioMedical Technologies and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced BioMedical Technologies's current ROC % is -263.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current ROC % of -263.53%. The current ROC % is -263.53%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current ROC % is -263.53% as of Jul. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.